Skip to main content
TipRanks
Go Ultimate75% OFF

Integrated Diagnostics Holdings (IDHC) AI Stock Analysis

27 Followers
GB:IDHC

Integrated Diagnostics Holdings

(LSE:IDHC)

Select Model
Rating:77Outperform
Price Target:$0.54▲(13.57% Upside)
Action:reiterated
Date:09/15/26

The overall score is driven primarily by strong financial performance and very positive earnings-call trends in revenue, margins, and profitability, supported by a relatively attractive valuation, while neutral technical signals and risks around geopolitics, working capital, and the Saudi ramp-up keep the stock below the top scoring tier.

Positive Factors
Broad-Based Revenue GrowthStrong growth across revenue, testing volume, and patient numbers indicates expanding utilization rather than reliance on pricing alone. Higher engagement and referral flow can support durable operating leverage, reinforce IDH’s market position, and provide a solid base for continued earnings growth.
Negative Factors
Working Capital PressureHigher receivables and inventory are absorbing more cash as the company expands and builds medical supplies. The resulting decline in net cash reduces financial flexibility, while sustained working-capital intensity could weaken cash conversion and limit internally funded investment.

Integrated Diagnostics Holdings (IDHC) vs. iShares MSCI United Kingdom ETF (EWC)

-40%-30%-20%-10%0%10%20%30%GB:IDHC-28.40%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$278.75M
Dividend Yield
5.32%
Average Volume (3M)
555.93K
Price to Earnings (P/E)
9.9
Beta (1Y)
0.59
Revenue Growth
―
EPS Growth
―
Country
UK
Employees
7,137
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Integrated Diagnostics Holdings Business Overview & Revenue Model

Company Description

Integrated Diagnostics Holdings plc (IDHC.L) functions as a leading consumer healthcare enterprise, offering a wide array of medical diagnostic services directly to its clientele. The company's comprehensive service catalog features around 2,000 dist...

How the Company Makes Money

IDHC makes money primarily by performing diagnostic tests and pathology services for patients referred by healthcare providers and billing for those services. Key revenue streams generally include (1) pathology services, where tissue and other specim...

Integrated Diagnostics Holdings Earnings Call Summary

Earnings Call Date:Sep 11, 2026(Q2-2026)|% Change Since:-7.88%|Next Earnings Date:Nov 21, 2018
Earnings Call SentimentPositive

The call was strongly positive overall. Highlights significantly outweighed the lowlights, with 37% revenue growth, record testing volume, expanding margins, 47% net profit growth, improved Nigeria performance, and rapid Saudi expansion. The main challenges were geopolitical uncertainty, constrained Sudan operations, Saudi Arabia remaining below break-even, higher working capital balances, lower net cash, and the decision not to pay an interim dividend.

Positive Updates

Strong Broad-Based First-Half Growth
IDH reported broad-based operational and financial growth in H1 2026, with revenue increasing 37% year-on-year to EGP 4.9 billion. Test volumes rose 20% to 23.6 million, average revenue per test increased 14% to EGP 206, and patients served increased 14% to 4.9 million.

Negative Updates

Geopolitical and Macroeconomic Uncertainty
Management said evolving macroeconomic conditions and regional developments may introduce volatility across parts of the Group's footprint. Egypt's inflation remained sensitive to currency movements and energy-related pressures, the Egyptian Pound experienced renewed pressure earlier in 2026, and management is monitoring potential effects on economic activity, patient volumes, and consumer sentiment.

Company Guidance

For 2026, management is forecasting revenue of EGP 11 billion, gross profit of 46%, EBITDA margin of 37%, and net profit margin of 20%; margins are expected “to have the same margins until the full year of 2026,” with Q3 and Q4 expected “to be resilient” and “a good second half of 2026 with high margins.” Egypt is expected to add “around 50 more branches in H2,” while Saudi Arabia’s plan is to open nine branches this year, with five opened and four to go, and to reach 50 branches in three years; Nigeria is not expected to open more branches, with the focus on increasing revenue, patient footprint, tests, and profitability from existing branches. Management said a 4% price increase implemented during the second quarter “will continue for the rest of the year,” but also said, “We are not planning to do any price increase for the rest of the year,” and confirmed that “for this quarter, there will be no dividend distribution.”

Integrated Diagnostics Holdings Financial Statement Overview

Summary

Robust revenue and profit growth, high-30s EBITDA margins, improving gross margin, and strong free cash flow support a solid financial profile, partly tempered by rising but still manageable leverage.

Income Statement

84Very Positive

Balance Sheet

72Positive

Cash Flow

77Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Mar 2023Mar 2022
Income Statement
Total Revenue9.17B7.86B5.72B4.12B3.61B5.22B
Gross Profit3.97B3.35B2.18B1.52B1.46B2.80B
EBITDA2.88B2.89B2.09B1.28B1.29B2.57B
Net Income1.51B1.26B1.08B510.30M541.11M1.41B
Balance Sheet
Total Assets9.31B8.60B7.13B5.77B5.30B6.24B
Cash, Cash Equivalents and Short-Term Investments1.96B2.13B1.75B860.51M815.92M2.35B
Total Debt1.68B1.61B1.47B1.18B1.18B858.74M
Total Liabilities4.59B4.46B3.63B2.67B2.85B3.44B
Stockholders Equity3.93B3.38B2.71B2.68B2.15B2.58B
Cash Flow
Free Cash Flow01.38B1.34B217.73M-100.11M2.01B
Operating Cash Flow01.90B1.57B543.66M208.73M2.27B
Investing Cash Flow0-552.92M-446.71M-243.94M990.11M-1.33B
Financing Cash Flow0-851.06M-749.00M-330.46M-1.62B-647.15M

Integrated Diagnostics Holdings Technical Analysis

Technical Analysis SentimentNegative
Last Price0.48

Price Trends

50DMA0.51Negative
100DMA0.52Negative
200DMA0.55Negative

Market Momentum

MACD-0.01Negative
RSI47.73Neutral
STOCH58.97Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IDHC, the sentiment is Negative. The current price of 0.48 is above the 20-day moving average (MA) of 0.48, below the 50-day MA of 0.51, and below the 200-day MA of 0.55, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 47.73 is Neutral, neither overbought nor oversold. The STOCH value of 58.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IDHC.

Integrated Diagnostics Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:IDHC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:BVXPGB:BVXP89OutperformGBP 102.93M13.5967.81%7.61%-1.10%0.32%
GB:IDHCGB:IDHC77Outperform$278.75M9.8839.61%5.32%――
GB:EKFGB:EKF64NeutralGBP 102.71M41.383.58%―2.26%-57.04%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:GDRGB:GDR49NeutralGBP 14.45M-0.82-1044.57%―65.60%74.84%
GB:ABDXGB:ABDX46NeutralGBP 21.48M-15.45-34.31%―30.42%43.16%
GB:CNSLGB:CNSL43NeutralGBP 3.45M-0.55-117.38%―-32.11%-559.65%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%75%GB:IDHCGB:BVXPGB:EKFGB:GDRGB:CNSLGB:ABDXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:IDHC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:IDHCIntegrated Diagnostics Holdings0.48-0.20-29.46%
GB:BVXPBioventix plc1970.00-17.97-0.90%
GB:EKFEKF Diagnostics Holdings24.00-2.20-8.40%
GB:GDRGenedrive plc0.900.1113.92%
GB:CNSLOmega Diagnostics1.45-0.80-35.56%
GB:ABDXAbingdon Health PLC8.501.0013.33%

Integrated Diagnostics Holdings Corporate Events

Regulatory Filings and Compliance

Insider-Related Share Purchase at Integrated Diagnostics Holdings

Positive
Oct 15, 2026

Integrated Diagnostics Holdings PLC disclosed a significant share purchase by Hena Holdings Ltd, a person closely associated with Chief Executive Officer Dr Hend El Sherbini. The transaction involved the acquisition of 15,580,812 ordinary shares at a...

Business Operations and StrategyDividendsFinancial Disclosures

IDH Delivers Strong H1 Growth as Founders Tighten Control and Cash Is Preserved for Expansion

Positive
Sep 11, 2026

Integrated Diagnostics Holdings reported strong top- and bottom-line growth in the first half of 2026, with revenues rising 37% to EGP 4.9 billion on the back of 20% higher test volumes and a 14% increase in revenue per test. Gross profit climbed 41%...

Business Operations and StrategyFinancial Disclosures

IDH Schedules Interim 2026 Results and Investor Call

Positive
Sep 4, 2026

Integrated Diagnostics Holdings, a London-listed provider of clinical pathology and radiology services across several Middle Eastern and African markets, plans to publish its unaudited financial results for the second quarter and first half of 2026 o...

Regulatory Filings and Compliance

Integrated Diagnostics Discloses Mandatory Offer Acceptance by CEO-Linked Investor

Neutral
Aug 17, 2026

Integrated Diagnostics Holdings disclosed a transaction involving Hena Holdings Ltd, a person closely associated with chief executive officer Dr Hend El Sherbini. The filing, made under UK Market Abuse Regulation, relates to ordinary shares of $0.25...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 15, 2026